160 related articles for article (PubMed ID: 36713566)
1. Platinum drugs-related safety profile: The latest five-year analysis from FDA adverse event reporting system data.
Feng G; Zhou X; Chen J; Li D; Chen L
Front Oncol; 2022; 12():1012093. PubMed ID: 36713566
[TBL] [Abstract][Full Text] [Related]
2. Adverse event profiles of platinum agents: data mining of the public version of the FDA adverse event reporting system, AERS, and reproducibility of clinical observations.
Sakaeda T; Kadoyama K; Okuno Y
Int J Med Sci; 2011; 8(6):487-91. PubMed ID: 21897761
[TBL] [Abstract][Full Text] [Related]
3. Data mining for adverse drug reaction signals of daptomycin based on real-world data: a disproportionality analysis of the US Food and Drug Administration adverse event reporting system.
Chen JJ; Huo XC; Wang SX; Wang F; Zhao Q
Int J Clin Pharm; 2022 Dec; 44(6):1351-1360. PubMed ID: 36178607
[TBL] [Abstract][Full Text] [Related]
4. Post-marketing safety of immunomodulatory drugs in multiple myeloma: A pharmacovigilance investigation based on the FDA adverse event reporting system.
Jiang T; Su H; Li Y; Wu Y; Ming Y; Li C; Fu R; Feng L; Li Z; Li L; Ni R; Liu Y
Front Pharmacol; 2022; 13():989032. PubMed ID: 36532784
[No Abstract] [Full Text] [Related]
5. Propofol-associated serious adverse events: an analysis of the FAERS database.
Xuan G; Zhang Y; Cui J; Zhou J; Sui C
Biotechnol Genet Eng Rev; 2023 Apr; ():1-14. PubMed ID: 37066882
[TBL] [Abstract][Full Text] [Related]
6. [Study on mining of signals of adverse drug reactions of entecavir and tenofovir disoproxil based on the US FAERS database].
Liu X; Chen L; Zhao L
Zhonghua Gan Zang Bing Za Zhi; 2021 Sep; 29(9):830-836. PubMed ID: 34638200
[No Abstract] [Full Text] [Related]
7. Adverse drug events in the prevention and treatment of COVID-19: A data mining study on the FDA adverse event reporting system.
Guo Q; Duan S; Liu Y; Yuan Y
Front Pharmacol; 2022; 13():954359. PubMed ID: 36506542
[No Abstract] [Full Text] [Related]
8. Postmarketing safety of anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS).
Omar NE; Fahmy Soliman AI; Eshra M; Saeed T; Hamad A; Abou-Ali A
ESMO Open; 2021 Dec; 6(6):100315. PubMed ID: 34864500
[TBL] [Abstract][Full Text] [Related]
9. Disproportionality analysis of quinolone safety in children using data from the FDA adverse event reporting system (FAERS).
Kong W; Mao W; Zhang L; Wu Y
Front Pediatr; 2022; 10():1069504. PubMed ID: 36714649
[TBL] [Abstract][Full Text] [Related]
10. Adverse reaction signals mining and hemorrhagic signals comparison of ticagrelor and clopidogrel: A pharmacovigilance study based on FAERS.
Tang S; Wu Z; Xu L; Wen Q; Zhang X
Front Pharmacol; 2022; 13():970066. PubMed ID: 36263117
[No Abstract] [Full Text] [Related]
11. A real-world pharmacovigilance analysis of FDA adverse event reporting system database for upadacitinib.
Wu Y; Wei M; Zhang J
Front Pharmacol; 2023; 14():1200254. PubMed ID: 37663269
[No Abstract] [Full Text] [Related]
12. Platinum agent-induced hypersensitivity reactions: data mining of the public version of the FDA adverse event reporting system, AERS.
Sakaeda T; Kadoyama K; Yabuuchi H; Niijima S; Seki K; Shiraishi Y; Okuno Y
Int J Med Sci; 2011; 8(4):332-8. PubMed ID: 21611115
[TBL] [Abstract][Full Text] [Related]
13. Commonality of drug-associated adverse events detected by 4 commonly used data mining algorithms.
Sakaeda T; Kadoyama K; Minami K; Okuno Y
Int J Med Sci; 2014; 11(5):461-5. PubMed ID: 24688309
[TBL] [Abstract][Full Text] [Related]
14. Safety of triazole antifungals: a pharmacovigilance study from 2004 to 2021 based on FAERS.
Chai S; Zhan JL; Zhao LM; Liu XD
Ther Adv Drug Saf; 2022; 13():20420986221143266. PubMed ID: 36545565
[TBL] [Abstract][Full Text] [Related]
15. Research on Beers Criteria and STOPP/START Criteria based on the FDA FAERS database.
Shao Q; Xu Y; Li M; Chu X; Liu W
Eur J Clin Pharmacol; 2021 Aug; 77(8):1147-1156. PubMed ID: 34170370
[TBL] [Abstract][Full Text] [Related]
16. Analysis of Clinical Factors in Olaparib-related Anemia Using Adverse Drug Event Reporting Databases.
Shiraishi C; Hirai T; Ogura T; Iwamoto T
Anticancer Res; 2023 Feb; 43(2):883-891. PubMed ID: 36697083
[TBL] [Abstract][Full Text] [Related]
17. Recommendations for the selection of nucleoside analogues as antihuman herpesvirus drugs: a real-world analysis of reported cases from the FDA adverse event reporting system.
Gao C; Dong X; Zhang J; Mao L; Guo C; Qin X; Zou Z
Expert Opin Drug Saf; 2024 Jun; ():. PubMed ID: 38943630
[TBL] [Abstract][Full Text] [Related]
18. Safety profile of carbapenems: Data mining of the FDA adverse events reporting system.
Ge W; Hu H; Li C; Wang L; Xia J
Int J Clin Pharmacol Ther; 2021 Sep; 59(9):594-602. PubMed ID: 33896448
[TBL] [Abstract][Full Text] [Related]
19. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
Welch HK; Kellum JA; Kane-Gill SL
Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
[TBL] [Abstract][Full Text] [Related]
20. Analysis of adverse events of renal impairment related to platinum-based compounds using the Japanese Adverse Drug Event Report database.
Naganuma M; Motooka Y; Sasaoka S; Hatahira H; Hasegawa S; Fukuda A; Nakao S; Shimada K; Hirade K; Mori T; Yoshimura T; Kato T; Nakamura M
SAGE Open Med; 2018; 6():2050312118772475. PubMed ID: 29770217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
